Targeting the Mycobacterium ulcerans cytochrome bc1:aa3 for the treatment of Buruli ulcer

Nicole Scherr; Raphael Bieri; Sangeeta Susan Thomas; Aurélie Chauffour; Nitin Pal Kalia; Paul‐Albert Schneide; Marie‐Thérèse Ruf; Araceli Lamelas; Malathy Sony Subramanian Manimekalai; Gerhard Grüber; Norihisa Ishii; Koichi Suzuki; Marcel Tanner; Garrett C. Moraski; Marvin J. Miller; Matthias Witschel; Vincent Jarlier; Gerd Pluschke; Kévin Pethe

doi:10.1038/s41467-018-07804-8

Abstract

to respire. As a result, Q203 is bactericidal at low dose against M. ulcerans replicating in vitro and in mice, making the drug a promising candidate for Buruli ulcer treatment.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Scherr et al. (2018) studied this question.

synapsesocial.com/papers/6a0373dc90b35e5741aee23f https://doi.org/10.1038/s41467-018-07804-8

View Full Paper

Ask AI

Bookmark

Share

Targeting the Mycobacterium ulcerans cytochrome bc1:aa3 for the treatment of Buruli ulcer

Abstract

Discussion

Cite This Study

Targeting the Mycobacterium ulcerans cytochrome bc1:aa3 for the treatment of Buruli ulcer

Abstract

Discussion

Cite This Study

Keep reading

Keep reading